BZ371A
Phase 2Small molecule
BZ371A is one of 93 small molecule programs targeting Efficacy. It is currently in Phase 2.
2
Indications
4
Total Trials
3
Active Trials
92
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
139 competitors in Efficacy
#DrugCompanyPhaseTrials
1Biaxin
AbbViePhase 3
Vabysmo
RochePhase 3
Paraplatin
AAvyxa
Phase 3
Insulin 320
Novo NordiskPhase 3
Zelhou
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 3
Cetaphil
GGalderma R&D
Phase 3
Aralen
SanofiPreclinical
Primaquine
SanofiPreclinical
Estrasorb
Novo NordiskPreclinical
Proamatine
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy2 trials
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BZ371A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBiozeus Biopharmaceutical S.A.